BTIG Research Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock

Haemonetics (NYSE:HAE - Get Free Report) had its price objective boosted by analysts at BTIG Research from $85.00 to $88.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the medical instruments supplier's stock. BTIG Research's target price would suggest a potential upside of 33.83% from the stock's current price.

HAE has been the topic of a number of other research reports. Citigroup dropped their price objective on Haemonetics from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, October 7th. Barrington Research restated an "outperform" rating and issued a $86.00 price target on shares of Haemonetics in a research note on Tuesday, October 21st. Needham & Company LLC reissued a "buy" rating and issued a $68.00 price objective (down from $84.00) on shares of Haemonetics in a research report on Thursday, August 7th. Weiss Ratings downgraded shares of Haemonetics from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Saturday, October 25th. Finally, Raymond James Financial lowered Haemonetics from a "strong-buy" rating to an "outperform" rating and lowered their target price for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $77.10.

View Our Latest Report on Haemonetics

Haemonetics Stock Up 29.6%

Shares of HAE stock traded up $15.04 on Thursday, hitting $65.76. The company's stock had a trading volume of 2,522,254 shares, compared to its average volume of 828,216. The firm's fifty day moving average price is $50.99 and its 200-day moving average price is $61.98. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of 20.01, a P/E/G ratio of 0.91 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business's revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Research analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

Institutional Trading of Haemonetics

A number of institutional investors have recently modified their holdings of the company. Quarry LP increased its position in Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after acquiring an additional 396 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock valued at $33,000 after purchasing an additional 165 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 567 shares during the period. Finally, Byrne Asset Management LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at approximately $42,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Featured Stories

• Five stocks we like better than Haemonetics
• Low PE Growth Stocks: Unlocking Investment Opportunities
• Tempus AI: Volatility Equates to Opportunity in AI Leader
• How to Calculate Return on Investment (ROI)
• Follow the Money: 3 Stocks With High Institutional Ownership
• What is the Dogs of the Dow Strategy? Overview and Examples
• Can Gold Mining Stocks Shine as the Metals Rally Falters?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Haemonetics Right Now?

Before you consider Haemonetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.

While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here